GNPX

Genprex, Inc.

0.24 USD

Last updated Dec 3, 23:13 UTC

Yesterday HIGH

$0.26

Yesterday LOW

$0.23

52w HIGH

$1.94

52w LOW

$0.19

EPS

-0.13

PE

-1.84

Next Earnings

Apr 1, 2024

Overview News Government Trades

Genprex, Inc. stock is down -25.31% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 December’s closed higher than November.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

genprex.com

Benzinga Newsdesk

Tue May 30, 2023

Genprex Receives Safety Review Committee Approval To Advance To Phase 2 Expansion Portion Of Acclaim-1 Clinical Trial Of REQORSA In Combination With Tagrisso In Advanced Non-Small Cell Lung Cancer
Benzinga Newsdesk

Thu May 25, 2023

Genprex Publishes Clinical Data From Phase 1 Portion Of Acclaim-1 Clinical Trial Evaluating REQORSA Immunogene Therapy In Non-Small Cell Lung Cancer At 2023 ASCO Annual Meeting

Results Show Combination of REQORSA® and Tagrisso® was Well Tolerated at All Three Dose Levels of Phase 1 Trial with Encouraging Evidence of Efficacy Observed
Lisa Levin

Mon Apr 24, 2023

Crude Oil Up 1.5%; Philips Shares Jump After Q1 Results

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday. The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16. The S&P 500, also fell, dropping, 0.01% to 4,132.91.
Lisa Levin

Mon Apr 24, 2023

Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment.
Lisa Levin

Mon Apr 24, 2023

US Stocks Turn Lower; Nasdaq Dips 100 Points

U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P 500, also fell, dropping, 0.32% to 4,120.38.
Michael Horton

Fri Apr 21, 2023

Genprex Files For Mixed-Securities Shelf Offering Of Up To $200M

-SEC Filing
Vandana Singh

Wed Apr 19, 2023

Genprex Touts Encouraging Preclinical Data From Lung Cancer Candidate

Genprex Inc (NASDAQ: GNPX) announced that its research collaborators presented preclinical data for the NPRL2 gene (also known as the TUSC4 gene).
Benzinga Newsdesk

Wed Apr 19, 2023

Genprex Highlights Presentation Of NPRL2 Gene Therapy Data By Collaborators
Benzinga Insights

Wed Apr 19, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Lisa Levin

Wed Apr 19, 2023

Why Sonnet BioTherapeutics Shares Are Trading Lower By Around 13%; Here Are 20 Stocks Moving Premarket

Gainers Clearmind Medicine Inc. (NASDAQ: CMND) jumped 69.3% to $0.8480 in pre-market trading after dropping 12% on Tuesday. Clearmind Medicine recently announced a $3.5 million public offering priced at $0.78 per share.